240 related articles for article (PubMed ID: 18945991)
1. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients.
Carrero JJ; Ortiz A; Qureshi AR; Martín-Ventura JL; Bárány P; Heimbürger O; Marrón B; Metry G; Snaedal S; Lindholm B; Egido J; Stenvinkel P; Blanco-Colio LM
Clin J Am Soc Nephrol; 2009 Jan; 4(1):110-8. PubMed ID: 18945991
[TBL] [Abstract][Full Text] [Related]
2. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease.
Urbonaviciene G; Martin-Ventura JL; Lindholt JS; Urbonavicius S; Moreno JA; Egido J; Blanco-Colio LM
Atherosclerosis; 2011 Dec; 219(2):892-9. PubMed ID: 21962403
[TBL] [Abstract][Full Text] [Related]
3. Soluble TWEAK and cardiovascular morbidity and mortality in chronic kidney disease patients.
Hassan SB; El-demery AB; Ahmed AI; Abukhalil RE
Arab J Nephrol Transplant; 2012 Jan; 5(1):27-32. PubMed ID: 22283863
[TBL] [Abstract][Full Text] [Related]
4. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease.
Valdivielso JM; Coll B; Martín-Ventura JL; Moreno JA; Egido J; Fernández E; Blanco-Colio LM
J Nephrol; 2013; 26(6):1105-13. PubMed ID: 23475462
[TBL] [Abstract][Full Text] [Related]
5. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio.
Moreno JA; Dejouvencel T; Labreuche J; Smadja DM; Dussiot M; Martin-Ventura JL; Egido J; Gaussem P; Emmerich J; Michel JB; Blanco-Colio LM; Meilhac O
Arterioscler Thromb Vasc Biol; 2010 Jun; 30(6):1253-62. PubMed ID: 20299688
[TBL] [Abstract][Full Text] [Related]
6. Endogenous erythropoietin and the association with inflammation and mortality in diabetic chronic kidney disease.
Wagner M; Alam A; Zimmermann J; Rauh K; Koljaja-Batzner A; Raff U; Wanner C; Schramm L
Clin J Am Soc Nephrol; 2011 Jul; 6(7):1573-9. PubMed ID: 21734083
[TBL] [Abstract][Full Text] [Related]
7. Decoy receptor 3, a novel inflammatory marker, and mortality in hemodialysis patients.
Hung SC; Hsu TW; Lin YP; Tarng DC
Clin J Am Soc Nephrol; 2012 Aug; 7(8):1257-65. PubMed ID: 22626963
[TBL] [Abstract][Full Text] [Related]
8. Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease.
Matsubara K; Stenvinkel P; Qureshi AR; Carrero JJ; Axelsson J; Heimbürger O; Bárány P; Alvestrand A; Lindholm B; Suliman ME
J Nephrol; 2009; 22(6):774-82. PubMed ID: 19967657
[TBL] [Abstract][Full Text] [Related]
9. The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients.
Liabeuf S; Barreto DV; Barreto FC; Chasseraud M; Brazier M; Choukroun G; Kamel S; Massy ZA
Nephrol Dial Transplant; 2010 Aug; 25(8):2596-602. PubMed ID: 20190248
[TBL] [Abstract][Full Text] [Related]
10. Circulating vascular endothelial growth factor (VEGF) and its soluble receptor 1 (sVEGFR-1) are associated with inflammation and mortality in incident dialysis patients.
Yuan J; Guo Q; Qureshi AR; Anderstam B; Eriksson M; Heimbürger O; Bárány P; Stenvinkel P; Lindholm B
Nephrol Dial Transplant; 2013 Sep; 28(9):2356-63. PubMed ID: 23828162
[TBL] [Abstract][Full Text] [Related]
11. Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD.
Fernández-Laso V; Sastre C; Valdivielso JM; Betriu A; Fernández E; Egido J; Martín-Ventura JL; Blanco-Colio LM
Clin J Am Soc Nephrol; 2016 Mar; 11(3):413-22. PubMed ID: 26728587
[TBL] [Abstract][Full Text] [Related]
12. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes.
Yilmaz MI; Sonmez A; Ortiz A; Saglam M; Kilic S; Eyileten T; Caglar K; Oguz Y; Vural A; Çakar M; Egido J; Altun B; Yenicesu M; Blanco-Colio LM; Carrero JJ
Clin J Am Soc Nephrol; 2011 Apr; 6(4):785-92. PubMed ID: 21330486
[TBL] [Abstract][Full Text] [Related]
13. Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients.
Honda H; Ueda M; Kojima S; Mashiba S; Michihata T; Takahashi K; Shishido K; Akizawa T
Atherosclerosis; 2012 Feb; 220(2):493-501. PubMed ID: 22119537
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol synthesis, cholesterol absorption, and mortality in hemodialysis patients.
Rogacev KS; Pinsdorf T; Weingärtner O; Gerhart MK; Welzel E; van Bentum K; Popp J; Menzner A; Fliser D; Lütjohann D; Heine GH
Clin J Am Soc Nephrol; 2012 Jun; 7(6):943-8. PubMed ID: 22461539
[TBL] [Abstract][Full Text] [Related]
15. Brain natriuretic peptide between traditional and nontraditional risk factors in hemodialysis patients: analysis of cardiovascular mortality in a two-year follow-up.
Selim G; Stojceva-Taneva O; Spasovski G; Georgievska-Ismail L; Zafirovska-Ivanovska B; Gelev S; Dzekova P; Trajcevska L; Trojacanec-Piponska S; Sikole A
Nephron Clin Pract; 2011; 119(2):c162-70. PubMed ID: 21757955
[TBL] [Abstract][Full Text] [Related]
16. Comparison of C-reactive protein and high-sensitivity C-reactive protein levels in patients on hemodialysis.
Helal I; Zerelli L; Krid M; ElYounsi F; Ben Maiz H; Zouari B; Adelmoula J; Kheder A
Saudi J Kidney Dis Transpl; 2012 May; 23(3):477-83. PubMed ID: 22569431
[TBL] [Abstract][Full Text] [Related]
17. Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial.
Depalma RG; Hayes VW; Chow BK; Shamayeva G; May PE; Zacharski LR
J Vasc Surg; 2010 Jun; 51(6):1498-503. PubMed ID: 20304584
[TBL] [Abstract][Full Text] [Related]
18. Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study.
Panichi V; Rizza GM; Paoletti S; Bigazzi R; Aloisi M; Barsotti G; Rindi P; Donati G; Antonelli A; Panicucci E; Tripepi G; Tetta C; Palla R;
Nephrol Dial Transplant; 2008 Jul; 23(7):2337-43. PubMed ID: 18305316
[TBL] [Abstract][Full Text] [Related]
19. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients.
Qureshi AR; Alvestrand A; Divino-Filho JC; Gutierrez A; Heimbürger O; Lindholm B; Bergström J
J Am Soc Nephrol; 2002 Jan; 13 Suppl 1():S28-36. PubMed ID: 11792759
[TBL] [Abstract][Full Text] [Related]
20. Soluble TWEAK level: is it a marker for cardiovascular disease in long-term hemodialysis patients?
Gungor O; Kircelli F; Asci G; Carrero JJ; Tatar E; Demirci MS; Ozbek SS; Ceylan N; Toz H; Ozkahya M; Ok E
J Nephrol; 2013; 26(1):136-43. PubMed ID: 22505251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
